Skip to content

Medical Affairs

Intelligence Hub

Overview

Home
My Work
Command Center

Plan & execute

Medical Plans
Launch Readiness
Budget & Resources
Risks & Decisions

Field & science

Engagements
Insights
Evidence Generation

Communicate

Publications
Congresses
Medical Information

Govern

Reports
Data Quality
Administration

Helixor Therapeutics

Sample data · FY2026

Scope·4 products·FY2026

HODr. Helen OkaforGlobal Head of Medical Affairs

EngagementsENG-0052

Congress meeting · Dr. Noor Nakamura

12 Sept 2026 · Phone · Dr. Noor Nakamura, Hospital La Paz · MSL Rachel Adeyemi · Vantrexa

SubmittedVeeva CRMENG-0052—

Capture insight from this engagement

Location: Hospital La Paz
Therapeutic area: Oncology
Country: Spain
Stakeholder tier: Tier 2
Strategic objective: Not linked
Initiative: Not linked
MSL: RARachel AdeyemiMSL, Oncology (UK & Ireland)
Product: Vantrexa (vantrelimab)

Topics discussed

Infusion-reaction management

Scientific content used

PD-L1 testing pathway infographic

Questions raised

Is there subgroup data for patients with untreated brain metastases?

Notes

Congress meeting with pathologist at Hospital La Paz. Discussed infusion-reaction management.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
2Submitted
3Reviewed

Follow-ups

No follow-ups recorded.

Quality ratings

1–5, rated at review

Available after review.

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0052

Audit history (0)

All create, update and approval events for this record

No audit events in sample data